Join
Live feed
·
PRReleasevia Quantisnow
Turning Point Therapeutics Inc. logo

Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study

ByQuantisnow·Wall Street's wire, on your screen.
TPTX· Turning Point Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TPTX (Turning Point Therapeutics Inc.) and more on Quantisnow.